Pay in 4 interest-free payments of $5.55 Learn more
Ships within 48 hours · Estimated delivery Aug 8 - Aug 13
Even as Wegovy, Mounjaro, and other GLP-1 therapies become household names on par with Tylenol and Kleenex, financially burdened payers and employers are beginning to restrict coverage and drop the drugs from their formularies
When the gut barrier is already under assault from a pathogen, Akkermansia activity can worsen the situation rather than improve it
Good news for people on GLP-1 therapy who hate needles: Trial data out this week shows that an experimental pill developed by Eli Lilly could offer an intriguing off-ramp
Below, doctors share how to avoid the three super common mistakes people make when discontinuing GLP-1s
The trial populations give a useful map of who tends to respond, and matching your own situation against that map saves a lot of trial and error
/assets/images/provider/photos/2775905.jpeg)
